RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed
and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and
pharmacokinetics of RD13-01 in patients.